Sanofi India Limited has announced its financial results for the quarter ended March 31, 2026, highlighting continued momentum in its insulin portfolio. Alongside financial performance, the company announced the conclusion of the tenures of two independent directors and the appointment of Mr. Rahul Bhatnagar as the new Chairman of the Board, effective April 30, 2026, as part of a broader corporate governance transition.
Financial Performance Highlights
For the quarter ended March 31, 2026, Sanofi India reported revenue from operations of ₹4,723 million. The company achieved a profit for the period of ₹1,026 million, demonstrating resilience in a competitive market. The insulin portfolio remains a key growth driver, delivering double-digit growth for the second consecutive quarter, reinforcing the company’s established equity within the diabetes injectable segment.
Leadership and Governance Transition
The company confirmed significant changes to its Board of Directors. The tenures of independent directors Mr. Aditya Narayan and Mrs. Usha Thorat will conclude at the close of business on April 29, 2026. The Board expressed its appreciation for their service. Consequently, Mr. Rahul Bhatnagar has been appointed as the Chairman of the Board, effective April 30, 2026.
Strategic Committee Reconstitution
In conjunction with the leadership changes, the company has reconstituted several key board committees effective April 30, 2026. These include the Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee, Risk Management Committee, and the Corporate Social Responsibility Committee. These adjustments ensure continued governance excellence across all operational facets of the business.
Future Outlook
Management noted that while the overall quarterly results were impacted by transactions relating to partnership transitions, the company remains committed to driving efficiency through targeted market initiatives and refined go-to-market strategies. With steady export sales despite global geopolitical challenges, the company continues to focus on strengthening its commercial footprint and expanding access to both established and innovative therapeutic solutions across India.
Source: BSE
